Evidence-based (S3) guideline for the treatment of psoriasis vulgaris - Update: “Therapeutic options” and “Efalizumab”

2009 ◽  
Vol 8 (1) ◽  
pp. 65-66 ◽  
Author(s):  
Alexander Nast ◽  
Matthias Augustin ◽  
Wolf-Henning Boehncke ◽  
Joachim Klaus ◽  
Ulrich Mrowietz ◽  
...  
Keyword(s):  
Psoriasis Vulgaris ◽  
Therapeutic Options ◽  
Evidence Based ◽  
S3 Guideline

scholarly journals German S3‐Guideline on the treatment of Psoriasis vulgaris, adapted from EuroGuiDerm – Part 2: Treatment monitoring and specific clinical or comorbid situations

2021 ◽  
Vol 19 (7) ◽  
pp. 1092-1115
Author(s):  
Alexander Nast ◽  
Andreas Altenburg ◽  
Matthias Augustin ◽  
Wolf‐Henning Boehncke ◽  
Peter Härle ◽  
...  
Keyword(s):  
Psoriasis Vulgaris ◽  
Treatment Monitoring ◽  
S3 Guideline

scholarly journals German S3‐Guideline on the treatment of Psoriasis vulgaris, adapted from EuroGuiDerm – Part 1: Treatment goals and treatment recommendations

2021 ◽  
Vol 19 (6) ◽  
pp. 934-150
Author(s):  
Alexander Nast ◽  
Andreas Altenburg ◽  
Matthias Augustin ◽  
Wolf‐Henning Boehncke ◽  
Peter Härle ◽  
...  
Keyword(s):  
Psoriasis Vulgaris ◽  
Treatment Recommendations ◽  
Treatment Goals ◽  
S3 Guideline

Methods Report: Update of the German S3 Guideline for the Treatment of Psoriasis vulgaris

2018 ◽  
Vol 16 (5) ◽  
Author(s):  
Matthew Gaskins ◽  
Corinna Dressler ◽  
Ricardo Niklas Werner ◽  
Alexander Nast
Keyword(s):  
Psoriasis Vulgaris ◽  
S3 Guideline

scholarly journals The complement system in liver diseases: Evidence-based approach and therapeutic options

2019 ◽  
Vol 2 ◽  
pp. 100017 ◽  
Author(s):  
Thomas Lung ◽  
Benjamin Sakem ◽  
Lorenz Risch ◽  
Reinhard Würzner ◽  
Giuseppe Colucci ◽  
...  
Keyword(s):  
Complement System ◽  
Liver Diseases ◽  
Therapeutic Options ◽  
Evidence Based ◽  
The Complement System

scholarly journals Primary Therapy of Early Breast Cancer: Evidence, Controversies, Consensus

2019 ◽  
Vol 79 (06) ◽  
pp. 591-604 ◽  
Author(s):  
Michael Untch ◽  
Christoph Thomssen ◽  
Ingo Bauerfeind ◽  
Michael Braun ◽  
Sara Y. Brucker ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Risk Assessment ◽  
Clinical Practice ◽  
Consensus Conference ◽  
Evidence Based ◽  
Primary Therapy ◽  
Therapeutic Decision ◽  
Everyday Clinical Practice ◽  
S3 Guideline ◽  
Benefit Risk Assessment

AbstractThe results of the international St. Gallen Consensus Conference for the treatment of patients with primary breast cancer were discussed this year by a working group of leading breast cancer experts in view of the therapy recommendations for everyday clinical practice in Germany. Three of the breast cancer experts are also members of this yearʼs St. Gallen panel. The comparison of the St. Gallen recommendations with the annually updated treatment recommendations of the AGO 2019 as well as the S3 guideline is useful, since the recommendations of the St. Gallen panel represent the opinions of experts from various countries and disciplines. The recommendations of the S3 guideline and AGO are based on evidence-based research of the literature. This yearʼs 16th St. Gallen conference featured the motto “Magnitude of clinical benefit”. In addition to the evidence-based data, each therapeutic decision must also undergo a benefit/risk assessment of the patientʼs individual situation and be discussed with the patient.

Methods report on the development of the European evidence-based (S3) guideline for the treatment of acne - update 2016

2016 ◽  
Vol 30 (8) ◽  
pp. e1-e28 ◽  
Author(s):  
A. Nast ◽  
S. Rosumeck ◽  
R. Erdmann ◽  
U. Alsharif ◽  
C. Dressler ◽  
...  
Keyword(s):  
Evidence Based ◽  
S3 Guideline

Evidence-based (S3) guidelines for the treatment of psoriasis vulgaris

2007 ◽  
Vol 5 (s3) ◽  
pp. 1-119 ◽  
Author(s):  
Alexander Nast ◽  
Ina B. Kopp ◽  
Matthias Augustin ◽  
Kirstin-Benita Banditt ◽  
Wolf-Henning Boehncke ◽  
...  
Keyword(s):  
Psoriasis Vulgaris ◽  
Evidence Based ◽  
S3 Guidelines
Sign in / Sign up

Export Citation Format

Share Document